Ronald C. Petersen neurologist
Petersen, Ronald C., 1946-
Petersen, Ronald C.
פטרסן, רונלד ס., 1946-
VIAF ID: 92371305 (Personal)
Permalink: http://viaf.org/viaf/92371305
Preferred Forms
- 200 _ | ‡a Petersen ‡b Ronald C. ‡f 1946-....
-
- 100 1 _ ‡a Petersen, Ronald C.
- 100 1 _ ‡a Petersen, Ronald C.
-
-
- 100 1 _ ‡a Petersen, Ronald C. ‡d 1946-
- 100 1 _ ‡a Petersen, Ronald C. ‡d 1946-
-
-
- 100 1 _ ‡a Petersen, Ronald C., ‡d 1946-
-
-
- 100 0 _ ‡a Ronald C. Petersen ‡c neurologist
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Choroba Alzheimera | |
Emerging perspectives in the management of Alzheimer's disease proceedings of a symposium held at the Fifth International Conference on Alzheimer's Disease and Related Disorders in Osaka, Japan ; 16 tables | |
Guía de la clínica Mayo sobre la enfermedad de Alzheimer, c2002: | |
Łagodne zaburzenia funkcji poznawczych | |
Mayo Clinic on Alzheimer's disease | |
Memory disorders research and clinical practice | |
Mild cognitive impairment aging to Alzheimer's disease | |
Mild cognitive impairment du vieillissement cérébral normal à la démence | |
Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease | |
Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. | |
The short test of mental status. Correlations with standardized psychometric testing. | |
Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. | |
Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. | |
Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults | |
Subjective cognitive decline and risk of MCI: The Mayo Clinic Study of Aging | |
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies | |
Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. | |
Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND | |
Suspected non-Alzheimer disease pathophysiology--concept and controversy | |
Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy | |
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. | |
Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. | |
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition | |
Tau-positron emission tomography correlates with neuropathology findings | |
Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease | |
Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. | |
Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. | |
TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. | |
Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. | |
Timing of Physical Activity, Apolipoprotein E ε4 Genotype, and Risk of Incident Mild Cognitive Impairment | |
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia | |
Total intracranial volume: normative values and lack of association with Alzheimer's disease. | |
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | |
Tracking the development of agrammatic aphasia: A tensor-based morphometry study. | |
Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. | |
Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging. | |
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid | |
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study | |
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease | |
TREM2 p.R47H substitution is not associated with dementia with Lewy bodies | |
Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia | |
Understanding the diagnostic capabilities of cognitive tests. | |
Untreated type 2 diabetes and its complications are associated with subcortical infarctions | |
Uptake of AV-1451 in meningiomas. | |
Use of cerebrospinal fluid flow rates measured by phase-contrast MR to predict outcome of ventriculoperitoneal shunting for idiopathic normal-pressure hydrocephalus. | |
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. | |
Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy | |
Utility of the DRS for predicting problems in day-to-day functioning | |
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. | |
Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia | |
Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. | |
Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly | |
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association | |
Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment | |
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). | |
Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. | |
What is the quality of life in the oldest old? | |
White matter hyperintensities: relationship to amyloid and tau burden | |
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging | |
White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition | |
Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment | |
Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease | |
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia | |
Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly | |
Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia | |
Zeroing out preventable disability: Daring to dream the impossible dream for dementia care: Recommendations for a national plan to advance dementia care and maximize functioning. | |
β-Amyloid PET and neuropathology in dementia with Lewy bodies | |
מיו קליניק על אלצהימר |